[Form 4] Genelux Corporation Insider Trading Activity

Rhea-AI Filing Summary

Genelux Corporation director Tyree James L reported insider grants and ownership changes on 08/27/2025. The filing discloses the grant of 22,283 restricted stock units (RSUs) under the Issuer's 2022 Equity Incentive Plan; each RSU represents the contingent right to receive one share of common stock upon vesting. After the RSU grant, the reporting person beneficially owned 68,074 shares.

The filing also shows an option grant of 28,576 stock options with a $3.64 exercise price, exercisable and expiring on 08/26/2035. The RSUs and options vest upon the earlier of the one-year anniversary of grant and the Issuer's next annual meeting of stockholders. The form was signed by an attorney-in-fact on 08/29/2025.

Positive

• 22,283 RSUs granted under the Issuer's 2022 Equity Incentive Plan representing contingent rights to receive one share each upon vesting
• 28,576 stock options granted with a $3.64 exercise price and an expiration date of 08/26/2035
• Post-transaction beneficial ownership of 68,074 shares reported for the reporting person

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received equity compensation totaling 50,859 instruments (22,283 RSUs and 28,576 options) under disclosed plan.

The filing documents routine insider equity grants rather than open-market purchases or sales. The RSUs are contingent rights to one share each and the options carry a $3.64 exercise price with an expiration date in 2035. Vesting is time-based, tied to a one-year anniversary or the next annual meeting. For valuation or dilution impact, the filing provides quantities and exercise price but does not disclose fair value, grant date fair value, or any cash proceeds received.

Corporate Governance Expert

TL;DR: This is a standard director equity award disclosure under the companys equity incentive plan.

The report identifies the awards as granted under the 2022 Equity Incentive Plan with explicit vesting conditions. The disclosure is complete regarding counts, exercise price for options, and vesting triggers. It is a governance-typical disclosure showing alignment of a director with equity compensation, with the form executed by an attorney-in-fact. The filing does not indicate any amendment, sale, or derivative disposition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tyree James L

(Last) (First) (Middle)

C/O GENELUX CORPORATION

2625 TOWNSGATE ROAD, SUITE 230

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GENELUX Corp [ GNLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		A(1)		22,283	A	$0	68,074	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.64	08/27/2025		A		28,576		(2)	08/26/2035	Common stock	28,576	$0	28,576	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") granted pursuant to the Issuer's 2022 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

2. The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.

	/s/ Thomas Zindrick, J.D. Attorney-in-Fact	08/29/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did GNLX director Tyree James report on Form 4?

The Form 4 reports a grant of 22,283 RSUs and a grant of 28,576 stock options with a $3.64 exercise price; post-transaction beneficial ownership is 68,074 shares.

Under which plan were the RSUs granted?

The RSUs were granted pursuant to the Issuer's 2022 Equity Incentive Plan and each RSU equals the contingent right to receive one share upon vesting.

When do the RSUs and options vest?

Both the RSUs and the shares subject to the option vest upon the earlier of (a) the one-year anniversary of the grant date and (b) the Issuer's next annual meeting of stockholders.

What is the exercise price and expiration for the options?

The reported stock options have an exercise price of $3.64 and an expiration date of 08/26/2035.

Who signed the Form 4 and when?

The Form 4 was signed by Thomas Zindrick, J.D., Attorney-in-Fact on 08/29/2025.